The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SLGL | +606.42% | -50.8% | -13.22% | -70% |
| S&P | +13.14% | +87.24% | +13.37% | +141% |
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.
The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.
The small-cap company announced promising results from a clinical trial.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.40M | -92.5% |
| Market Cap | $81.20M | 328.7% |
| Market Cap / Employee | $2.39M | 0.0% |
| Employees | 34 | -5.6% |
| Net Income | -$5.94M | -1523.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.71M | -50.0% |
| Accounts Receivable | $9.85M | 40.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.59M | -35.8% |
| Short Term Debt | $0.49M | 27.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.17% | -2.6% |
| Return On Invested Capital | -37.94% | 2.0% |
No data available for this period.
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.90 | 0.72 | 1.02 | 2.55 | 366.67% |
| Price to Sales | 2.25 | 1.20 | 0.86 | 4.28 | 164.59% |
| Price to Tangible Book Value | 7.47 | 4.17 | 1.02 | 2.55 | -53.06% |
| Return on Equity | -31.4% | -49.4% | -10.2% | -29.6% | 20.33% |
| Total Debt | $1.31M | $1.18M | $1.18M | $1.08M | -17.08% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
